By REUTERSFEB. 4, 2015
Merck & Company said on Wednesday that American regulators intended to rescind the “breakthrough therapy” designation for its combination treatment for hepatitis C because other new drugs were available, a decision that could delay approval of the Merck product by several months. The Food and Drug Administration gives the designation to medicines it deems likely to demonstrate “substantial improvement” over existing drugs. The designation has hastened approval of some drugs by two to three months. Analysts said Merck’s two-drug treatment would most likely now require a standard 10-month review.A version of this brief appears in print on February 5, 2015, on Page B2 of the New York edition with the headline: Merck Expects Delay for a Hepatitis C Therapy.  Order Reprints| Today's Paper|Subscribe

We’re interested in your feedback on this page. Tell us what you think.